← Leaderboards
Saami K Yazdani
University Of South Alabama
$3,381,301
Attributed
$5,189,552
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,189,552 · 4
By mechanism
R01$4,776,418 · 3
R15$413,134 · 1
Top collaborators
- Barbara D. Boyan3 shared
- Emmanuel C. Opara3 shared
- Justin Saul3 shared
- Bryan W. Tillman2 shared
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsCardiovascular SystemSafetyTissuesFractureAffectRestenosisProliferatingStentsPerfusionCellsHealingBlood VesselsCathetersEndothelial CellsIn VivoArteriesDesignBioreactorsAntiproliferative DrugsEndotheliumEmbolismLiquid SubstancePrevent
Grant awards (10)
A Retrievable, Chambered Stentgraft to Achieve Localized, High Intensity Drug Delivery for Treatment of Vascular Restenosis$676,163
R01 · FY2025 · HL
Sustained regulation of hypothalamus-pituitary-ovary hormones with tissue-engineered ovarian constructs as a treatment for osteoporosis in females$490,107
R01 · FY2025 · AR
A Retrievable, Chambered Stentgraft to Achieve Localized, High Intensity Drug Delivery for Treatment of Vascular Restenosis$687,036
R01 · FY2024 · HL
Sustained regulation of hypothalamus-pituitary-ovary hormones with tissue-engineered ovarian constructs as a treatment for osteoporosis in females$494,133
R01 · FY2024 · AR
Sustained regulation of hypothalamus-pituitary-ovary hormones with tissue-engineered ovarian constructs as a treatment for osteoporosis in females$517,962
R01 · FY2023 · AR
Local delivery of smooth muscle cell targeted aptamer to inhibit neointimal growth and accelerate vascular healing$386,338
R01 · FY2023 · EB · contact PI
Local delivery of smooth muscle cell targeted aptamer to inhibit neointimal growth and accelerate vascular healing$448,902
R01 · FY2022 · EB · contact PI
Local delivery of smooth muscle cell targeted aptamer to inhibit neointimal growth and accelerate vascular healing$517,916
R01 · FY2021 · EB · contact PI
Local delivery of smooth muscle cell targeted aptamer to inhibit neointimal growth and accelerate vascular healing$557,861
R01 · FY2020 · EB · contact PI
A Novel Drug Delivery System to Treat Peripheral Arterial Disease$413,134
R15 · FY2016 · HL · contact PI